Clinical trial NCT00684203 (phase 2, status: completed)
Conditions: atherosclerosis, myocardial ischemia, myocardial infarction
ICD codes: I67.2, I70.90, I70.91, I70.0, I70.1, I70.8, I25.83, I25.6, P29.4, I25.2, I21.9, I21.A1, I21.A9, I21.4, I22.2, I23.8
Drugs: vorapaxar, placebo, aspirin, clopidogrel
SMILES: [H][C@@]12C[C@]3([H])C[C@@H](CC[C@@]3([H])[C@H](\C=C\C3=CC=C(C=N3)C3=CC(F)=CC=C3)[C@]1([H])[C@@H](C)OC2=O)NC(=O)OCC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(=O)OC1=CC=CC=C1C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women aged 18 years or more with history of cardiac ischemia related chest
             discomfort of > 10 minutes duration < 24 hours prior to randomization, and having at
             least 1 of the following A or B. Participants who are planned to undergo PCI will be
             the target participants.

               -  A: Positive biomarkers [Elevated troponin I or creatinine kinase MB isozyme
                  greater than the site's upper limit of normal (ULN)] at or before registration

               -  B: Electrocardiogram (ECG) changes: ST segment depression >= 0.1 mV (>=1 mm), or
                  transient (<30 minutes) ST segment elevation >= 0.1 mV (>=1 mm) in at least 2
                  contiguous leads

          -  Willing to give appropriate informed consent and complete all study-related
             procedures, and able to adhere to dosing and all visit schedules.

          -  Women of child-bearing potential (all postmenarchal women who are <1 years menopausal
             or who have not had surgical sterilization or a hysterectomy are considered to be
             women of child-bearing potential) must agree to use a medically accepted method of
             contraception while receiving protocol-specified medication, and for 60 days after
             stopping the medication.

        Exclusion Criteria:

          -  Pregnant and nursing mothers (premenopausal women should have a negative pregnancy
             test result confirmed before enrollment)

          -  Any serious illness or any condition that the investigator feels would pose a
             significant hazard to the participant if investigational therapy were initiated

          -  known hypersensitivity to any component of the current investigational product;

          -  Participation in a study of experimental therapy or use of any investigational drug
             within 30 days before enrollment

          -  Member of the staff personnel directly involved with this study;

          -  Family member of the investigational study staff;

          -  History of a bleeding diathesis, or evidence of active abnormal bleeding within 30
             days before enrollment

          -  History of a hemorrhagic stroke at any time

          -  Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure
             >110 mm Hg) while receiving therapy;

          -  Major surgery within 2 weeks prior to enrollment

          -  Known platelet count <100,000/mm^3

          -  Uncontrolled cardiac arrhythmia;

          -  Known impairment of renal function (serum creatinine >2.0 mg/dL [>176.8 umol/L]),
             dysproteinemia, nephrotic syndrome, or other renal disease;

          -  Active or chronic hepatobiliary or hepatic disease, or aspartate aminotransferase
             (AST) or alanine aminotransferase (ALT) activity more than two times greater than the
             upper limit of the laboratory reference range

          -  Anticipated staged PCI

          -  Concurrent or anticipated treatment with warfarin, factor Xa inhibitor, direct
             thrombin inhibitor, or antiplatelet agents except aspirin and ticlopidine after
             enrollment

          -  Anticipated intracoronary brachytherapy